サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1559715

酵素結合免疫吸着測定法（Elisa）試験の世界市場

Enzyme-linked Immunosorbent Assay (Elisa) Testing

出版日
ページ情報
英文 163 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
酵素結合免疫吸着測定法（Elisa）試験の世界市場
出版日: 2024年09月24日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 163 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

酵素結合免疫吸着測定法（Elisa）試験の世界市場は2030年までに16億米ドルに達する見込み

2023年に9億6,210万米ドルと推定される酵素結合免疫吸着測定法（Elisa）試験の世界市場は、分析期間2023-2030年にCAGR 7.7%で成長し、2030年には16億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるサンドイッチELISA検査は、CAGR 7.9%を記録し、分析期間終了時には7億8,410万米ドルに達すると予測されます。間接ELISA検査セグメントの成長率は、分析期間中CAGR 6.5%と推定されます。

米国市場は2億6,470万米ドルと推定、中国はCAGR 7.1％で成長予測

米国の酵素結合免疫吸着測定法（Elisa）試験市場は、2023年に2億6,470万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR7.1％を追いかけ、2030年までに2億4,800万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.2%と6.1%と予測されています。欧州では、ドイツがCAGR約6.2%で成長すると予測されています。

世界の酵素結合免疫吸着測定法（Elisa）試験市場- 主要動向と促進要因のまとめ

酵素結合免疫吸着測定法（Elisa）試験は診断と調査にどのような革命をもたらすか？

酵素結合免疫吸着測定法（Elisa）試験は、タンパク質、ホルモン、抗体、その他の生体分子を高感度かつ特異的に検出・定量する方法を提供することで、診断と調査に革命をもたらしています。臨床検査室、製薬研究、バイオテクノロジーで広く使用されているELISA検査は、感染症の診断、免疫反応のモニタリング、がん、HIV、自己免疫疾患などの様々な健康状態に関連するバイオマーカーの検出に不可欠です。特定の抗原や抗体を正確に測定できるELISAは、ヘルスケアプロバイダーにとっても研究者にとっても不可欠なツールです。この技術は汎用性が高いため、疾病診断、ワクチン開発、薬効試験、食品安全モニタリングなどに応用できます。正確で信頼性が高く、費用対効果の高い診断法への需要が高まる中、ELISA検査は公衆衛生、医学研究、治療開発を推進する上で重要な役割を果たし続け、タイムリーで効果的な介入の基盤を提供しています。

ELISA検査の機能性を高める技術革新とは？

自動化、多重化、ポイントオブケア（POC）検査における技術革新は、ELISA検査の機能性を大幅に向上させています。自動化は、ハイスループットスクリーニングを可能にし、人為的ミスを減らし、分析スピードを向上させることで、ELISAワークフローを一変させました。ロボット分注、自動プレートリーダー、統合ソフトウェアを含む自動ELISAシステムにより、検査室は数百または数千のサンプルを同時に処理できるようになり、効率が向上し、診断結果までの所要時間が短縮されます。これらのシステムはまた、手順を標準化し、異なる検査間で一貫した結果を保証し、手作業で起こりうるばらつきを減少させる。自動化は、迅速な検体処理がタイムリーな意思決定に不可欠な大規模臨床診断、製薬研究、疫学調査において特に重要です。

1つのサンプルで複数の分析物を測定できるマルチプレキシングは、ELISA技術におけるもう一つの大きな進歩です。従来のELISA検査では一度に1つの標的を測定するのが一般的でしたが、マルチプレックスELISAキットでは複数のバイオマーカーを同時に検出・定量することができます。この技術革新により、血液や血清などの複雑な生物学的サンプルの分析に必要な時間とリソースが大幅に削減され、1回のアッセイで包括的なデータが得られます。Multiplex ELISAは、疾患メカニズムや治療効果を理解するために複数のサイトカイン、ホルモン、疾患マーカーを測定する必要がある調査において特に有用です。また、複数のバイオマーカーを同時に測定することで、個々の患者に合った治療を行うことができる個別化医療においても、この機能は有益です。

ポイント・オブ・ケア（POC）ELISA検査はもう一つの画期的な進歩であり、クリニックや遠隔地、あるいは自宅など、従来の検査室以外でもELISA検査を実施できるようになった。ポータブルELISA装置は、迅速な診断結果をその場で、多くの場合数分以内に得られるように設計されています。これらのシステムは、迅速な診断と治療が重要な低資源環境や緊急時に特に有用です。HIV、肝炎、COVID-19などの疾患に対するPOC ELISA検査が開発されたことで、診断へのアクセスが大幅に拡大し、十分なサービスを受けていない人々の医療提供が改善されました。これらのポータブル・システムは、専門家でなくても操作できる簡素化されたワークフローを備えていることが多く、ELISA技術の利用範囲を広げています。

ナノテクノロジーはELISA検査の感度も高めています。金ナノ粒子などのナノ材料は、シグナルを増幅し検出限界を向上させるためにELISAアッセイに組み込まれつつあり、極低濃度のバイオマーカーの検出を可能にしています。このことは、特定の抗原や抗体の濃度が低いことを特定することで、早期介入や患者の予後改善につながる、疾患の早期発見において特に重要です。このような感度の向上は、ELISA検査の限界を押し広げ、分子レベルでのより正確な診断と研究を可能にしています。

ELISA検査は病気の診断と治療にどのような影響を与えるのか？

ELISA検査は、血液、唾液、尿、その他の生物学的サンプル中の疾患関連バイオマーカーを検出するための、信頼性が高く、感度が高く、利用しやすい方法を提供することにより、疾患の診断と治療に大きな影響を与えます。ELISAの主な利点のひとつは、感染症に関連する抗体、抗原、その他のタンパク質を検出できることであり、HIV、肝炎、ライム病、COVID-19のような疾患の診断に不可欠なツールとなっています。例えばHIV診断では、ELISAはしばしばウイルスに対する抗体の存在を検出する最初のスクリーニング検査として用いられます。このような感染症の早期発見は、治療を開始し、病気の進行を防ぎ、トランスミッションを減らすために極めて重要です。

腫瘍学では、PSA（前立腺特異抗原）やCA-125（がん抗原125）などの腫瘍マーカーの測定にELISA検査が広く用いられており、がんの診断や進行のモニタリングに役立っています。これらのマーカーを定量することにより、臨床医は腫瘍の活動性を評価し、治療効果を評価し、再発を検出することができます。ELISA検査の高い特異性により、これらのマーカーは複雑な生物学的試料でも正確に測定することができ、個別化された治療計画に不可欠な情報を提供します。同様に、狼瘡や関節リウマチのような自己免疫疾患では、ELISAは特定の自己抗体の存在を検出するために用いられ、臨床医がこれらの疾患をより効果的に診断・管理するのに役立っています。

診断に加えて、ELISA検査はワクチンや治療に対する免疫反応のモニタリングにおいても重要な役割を果たしています。例えば、ワクチン研究において、ELISAはワクチン接種に反応する抗体の産生を測定し、ワクチンの有効性と防御期間に関する知見を提供することができます。これはCOVID-19ワクチンの開発において特に重要であり、ELISA検査は臨床試験における免疫応答の評価に用いられました。ELISAは治療薬モニタリングにも使用され、血液中の薬物濃度を測定することで、臨床医が生物学的製剤やその他の治療薬を患者に最適な用量投与していることを確認するのに役立っています。

治療方針の決定におけるELISAの役割は、ヒトヘルスケアにとどまらないです。獣医学では、ELISA検査は牛の結核や鳥インフルエンザなどの動物の病気を検出するために使用され、動物の健康を守り、人畜共通感染症が人に広がるのを防ぐのに役立っています。さらにELISAは、アレルゲン、病原体、汚染物質を検出し、食品が安全基準を満たし、有害物質が含まれていないことを保証するために、食品安全検査で広く使用されています。

ELISA検査は、正確でタイムリーかつ費用対効果の高い診断法を提供することで、患者ケアを大幅に改善し、疾病管理を強化し、さまざまな医療・科学用途でより良い結果をサポートします。

ELISA検査市場の成長を促進する動向は？

ELISA検査市場の成長を牽引している動向には、感染症の蔓延、がんの早期発見に対する需要の高まり、個別化医療の拡大、自動化・多重化技術の進歩などがあります。HIV、肝炎、最近ではCOVID-19などの感染症による世界の負担の増大は、ELISA検査の需要を煽る最も大きな要因の一つです。ヘルスケアシステムがこれらの疾病の蔓延抑制に注力する中、ELISAは、特に有病率の高い地域において、大規模な診断スクリーニングのための重要なツールとなっています。パンデミック（世界的大流行）の脅威に対応するため、迅速で正確、かつ利用しやすい診断検査が必要とされていることが、臨床およびポイントオブケアの両環境におけるELISA検査の採用をさらに加速しています。

がんの早期発見に対する需要の高まりも、ELISA市場を牽引する大きな動向です。がんの罹患率が世界的に上昇を続ける中、治療が最も効果的な初期の段階でがんを検出できる診断ツールの開発が重視されるようになっています。腫瘍マーカーやその他のがん関連タンパク質を測定できるELISAは、特に前立腺がん、卵巣がん、乳がんのスクリーニング・プログラムにおいて、早期発見戦略に欠かせないものとなっています。ELISAがリキッドバイオプシーや分子診断法などの他の診断技術と統合されることで、より包括的で正確ながん検出ソリューションが提供され、がん領域における役割が強化されることが期待されます。

個別化医療の成長もELISA検査市場の拡大に寄与しています。個別化医療は、個々の患者に合わせた治療を行うためのバイオマーカーの同定に依存しており、ELISAはこれらのバイオマーカーを測定するための重要なツールです。自己免疫疾患、心血管疾患、がんなどの疾患では、個別化された治療計画は、ELISAが提供する正確なバイオマーカーデータに依存しています。精密医療の分野が成長するにつれ、バイオマーカー探索、医薬品開発、個別化治療モニタリングをサポートするELISA検査の需要が高まることが予想されます。

自動化と多重化技術の進歩は、ELISA検査をより効率的でスケーラブルなものにし、成長をさらに促進しています。自動ELISAシステムは人件費を削減し、人為的ミスを最小限に抑え、大規模な臨床診断や研究に不可欠なハイスループット検査を可能にしています。複数のバイオマーカーを1回のアッセイで測定できるマルチプレックスELISAは、ワークフローを合理化し、各サンプルからより包括的なデータを提供します。このような技術革新は、正確性と一貫性を維持しながら検査能力を高めようとする検査室にとって、ELISAをより魅力的なものにしています。

規制・業界標準もELISA市場の成長に寄与しています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関が、医薬品の安全性、ワクチンの有効性、診断精度についてより厳格なガイドラインを施行する中、ELISA検査はコンプライアンスを確保する上でますます重要になってきています。さらに、世界保健機関（WHO）による感染症対策など、疾病の制御と予防に重点を置いた世界・ヘルス・イニシアチブの台頭により、信頼性の高いELISAベースの診断薬に対する需要が高まっています。

こうした動向は、診断、研究、個別化医療におけるELISA検査の重要性が高まっていることを浮き彫りにしています。技術の進歩によりELISA検査の精度、スピード、アクセシビリティが向上し続ける中、複雑化するヘルスケアの現場において、正確で信頼性が高く、拡張性のある診断ソリューションが求められていることから、市場は持続的な成長を遂げるものと思われます。

調査対象企業の例（全22社）

  • Abcam PLC
  • American Laboratory Products Company（ALPCO）
  • Apollo Diagnostics
  • Assay Biotechnology Company, Inc.
  • Astra Biotech GmbH
  • Avioq, Inc.
  • Awareness Technology, Inc.
  • Axispharm Laboratories Ltd.
  • Biogenes
  • bioMerieux SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11837

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market to Reach US$1.6 Billion by 2030

The global market for Enzyme-linked Immunosorbent Assay (Elisa) Testing estimated at US$962.1 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Sandwich ELISA Testing, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$784.1 Million by the end of the analysis period. Growth in the Indirect ELISA Testing segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$264.7 Million While China is Forecast to Grow at 7.1% CAGR

The Enzyme-linked Immunosorbent Assay (Elisa) Testing market in the U.S. is estimated at US$264.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$248.0 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market - Key Trends and Drivers Summarized

How Is Enzyme-Linked Immunosorbent Assay (ELISA) Testing Revolutionizing Diagnostics and Research?

Enzyme-Linked Immunosorbent Assay (ELISA) testing is revolutionizing diagnostics and research by providing a highly sensitive and specific method for detecting and quantifying proteins, hormones, antibodies, and other biomolecules. Widely used in clinical laboratories, pharmaceutical research, and biotechnology, ELISA tests are essential for diagnosing infectious diseases, monitoring immune responses, and detecting biomarkers related to various health conditions, including cancer, HIV, and autoimmune disorders. The ability to measure specific antigens or antibodies with precision makes ELISA an indispensable tool for both healthcare providers and researchers. The technique’s versatility allows it to be applied in disease diagnostics, vaccine development, drug efficacy testing, and food safety monitoring. As the demand for accurate, reliable, and cost-effective diagnostic methods grows, ELISA testing continues to play a critical role in advancing public health, medical research, and therapeutic development, providing the foundation for timely and effective interventions.

What Innovations Are Enhancing the Functionality of ELISA Testing?

Innovations in automation, multiplexing, and point-of-care (POC) testing are significantly enhancing the functionality of ELISA tests. Automation has transformed ELISA workflows by allowing high-throughput screening, reducing human error, and increasing the speed of analysis. Automated ELISA systems, which include robotic pipetting, automated plate readers, and integrated software, enable laboratories to process hundreds or thousands of samples simultaneously, improving efficiency and reducing turnaround time for diagnostic results. These systems also standardize procedures, ensuring consistent results across different tests and reducing variability that can occur with manual processes. Automation is particularly important in large-scale clinical diagnostics, pharmaceutical research, and epidemiological studies where the rapid processing of samples is essential for timely decision-making.

Multiplexing, which allows multiple analytes to be measured in a single sample, is another major advancement in ELISA technology. Traditional ELISA tests typically measure one target at a time, but multiplex ELISA kits can detect and quantify several biomarkers simultaneously. This innovation significantly reduces the time and resources needed to analyze complex biological samples, such as blood or serum, providing comprehensive data in a single assay. Multiplex ELISA is particularly useful in research settings where multiple cytokines, hormones, or disease markers need to be measured to understand disease mechanisms or treatment efficacy. This capability is also beneficial in personalized medicine, where simultaneous measurement of multiple biomarkers helps tailor treatments to individual patients.

Point-of-care (POC) ELISA testing represents another breakthrough, making it possible to perform ELISA tests outside of traditional laboratories, such as in clinics, remote areas, or even at home. Portable ELISA devices are designed to provide rapid, on-site diagnostic results, often within minutes. These systems are particularly valuable in low-resource settings or during emergencies, where quick diagnosis and treatment are critical. The development of POC ELISA tests for diseases like HIV, hepatitis, and COVID-19 has greatly expanded access to diagnostics, improving healthcare delivery in underserved populations. These portable systems are often user-friendly, with simplified workflows that can be operated by non-specialists, broadening the reach of ELISA technology.

Nanotechnology is also enhancing the sensitivity of ELISA tests. Nanomaterials, such as gold nanoparticles, are being integrated into ELISA assays to amplify signals and improve detection limits, making it possible to detect extremely low concentrations of biomarkers. This is particularly important in early disease detection, where identifying low levels of a specific antigen or antibody can lead to earlier interventions and better patient outcomes. These advancements in sensitivity are helping to push the boundaries of ELISA testing, allowing for more accurate diagnosis and research at the molecular level.

How Does ELISA Testing Impact Disease Diagnosis and Treatment?

ELISA testing has a profound impact on disease diagnosis and treatment by providing a reliable, sensitive, and accessible method for detecting disease-related biomarkers in blood, saliva, urine, or other biological samples. One of the primary benefits of ELISA is its ability to detect antibodies, antigens, and other proteins associated with infectious diseases, making it a crucial tool for diagnosing conditions like HIV, hepatitis, Lyme disease, and COVID-19. In HIV diagnostics, for example, ELISA is often used as an initial screening test to detect the presence of antibodies against the virus. Early detection of such infections is critical for initiating treatment, preventing disease progression, and reducing transmission.

In oncology, ELISA tests are widely used to measure tumor markers, such as PSA (prostate-specific antigen) or CA-125 (cancer antigen 125), which help in diagnosing and monitoring cancer progression. By quantifying these markers, clinicians can assess tumor activity, evaluate the effectiveness of treatments, and detect recurrences. The high specificity of ELISA tests ensures that these markers can be accurately measured even in complex biological samples, providing essential information for personalized treatment planning. Similarly, in autoimmune diseases like lupus or rheumatoid arthritis, ELISA is used to detect the presence of specific autoantibodies, helping clinicians diagnose and manage these conditions more effectively.

In addition to diagnostics, ELISA testing plays a critical role in monitoring the immune response to vaccines and therapies. For example, in vaccine research, ELISA can measure the production of antibodies in response to vaccination, providing insights into vaccine efficacy and duration of protection. This has been particularly important during the development of COVID-19 vaccines, where ELISA tests were used to assess immune responses in clinical trials. ELISA is also used in therapeutic drug monitoring, where it helps clinicians ensure that patients are receiving optimal doses of biologics or other therapies by measuring drug levels in the blood.

ELISA’s role in guiding treatment decisions extends beyond human healthcare. In veterinary medicine, ELISA tests are used to detect diseases in animals, such as bovine tuberculosis or avian influenza, helping to protect animal health and prevent the spread of zoonotic diseases to humans. Additionally, ELISA is widely employed in food safety testing to detect allergens, pathogens, and contaminants, ensuring that food products meet safety standards and are free from harmful substances.

By providing accurate, timely, and cost-effective diagnostics, ELISA testing significantly improves patient care, enhances disease management, and supports better outcomes across a range of medical and scientific applications.

What Trends Are Driving Growth in the ELISA Testing Market?

Several trends are driving growth in the ELISA testing market, including the increasing prevalence of infectious diseases, the rising demand for early cancer detection, the growth of personalized medicine, and advancements in automation and multiplexing technologies. The growing global burden of infectious diseases, such as HIV, hepatitis, and more recently, COVID-19, is one of the most significant factors fueling demand for ELISA tests. As healthcare systems focus on controlling the spread of these diseases, ELISA is a key tool for large-scale diagnostic screening, particularly in high-prevalence regions. The need for rapid, accurate, and accessible diagnostic tests in response to pandemic threats has further accelerated the adoption of ELISA testing in both clinical and point-of-care settings.

The rising demand for early cancer detection is another major trend driving the ELISA market. As cancer rates continue to increase globally, there is a growing emphasis on developing diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. ELISA’s ability to measure tumor markers and other cancer-related proteins makes it an essential part of early detection strategies, particularly in screening programs for prostate, ovarian, and breast cancer. The integration of ELISA with other diagnostic technologies, such as liquid biopsies and molecular diagnostics, is expected to enhance its role in oncology, offering more comprehensive and accurate cancer detection solutions.

The growth of personalized medicine is also contributing to the expansion of the ELISA testing market. Personalized medicine relies on the identification of biomarkers to tailor treatments to individual patients, and ELISA is a key tool for measuring these biomarkers. In conditions like autoimmune diseases, cardiovascular disorders, and cancers, personalized treatment plans depend on precise biomarker data, which ELISA provides. As the field of precision medicine grows, demand for ELISA testing to support biomarker discovery, drug development, and personalized treatment monitoring is expected to rise.

Advancements in automation and multiplexing technologies are further driving growth by making ELISA testing more efficient and scalable. Automated ELISA systems are reducing labor costs, minimizing human error, and enabling high-throughput testing, which is crucial for large-scale clinical diagnostics and research. Multiplex ELISA, which allows multiple biomarkers to be measured in a single assay, is streamlining workflows and providing more comprehensive data from each sample. These innovations are making ELISA more appealing for laboratories seeking to increase testing capacity while maintaining accuracy and consistency.

Regulatory and industry standards are also contributing to the growth of the ELISA market. As regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), enforce stricter guidelines on drug safety, vaccine efficacy, and diagnostic accuracy, ELISA testing is becoming increasingly important for ensuring compliance. Additionally, the rise of global health initiatives focused on disease control and prevention, such as the World Health Organization’s (WHO) efforts to combat infectious diseases, is increasing the demand for reliable ELISA-based diagnostics.

These trends highlight the growing importance of ELISA testing in diagnostics, research, and personalized medicine. As technological advancements continue to improve the accuracy, speed, and accessibility of ELISA tests, the market is poised for sustained growth, driven by the need for precise, reliable, and scalable diagnostic solutions in an increasingly complex healthcare landscape.

Select Competitors (Total 22 Featured) -

  • Abcam PLC
  • American Laboratory Products Company (ALPCO)
  • Apollo Diagnostics
  • Assay Biotechnology Company, Inc.
  • Astra Biotech GmbH
  • Avioq, Inc.
  • Awareness Technology, Inc.
  • Axispharm Laboratories Ltd.
  • Biogenes
  • bioMerieux SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Bolstering Demand for ELISA Testing
    • Increasing Use of ELISA in Drug Monitoring and Pharmaceutical Applications
    • Impact of Global Health Initiatives on Infectious Disease Detection via ELISA
    • Integration of Automation in ELISA Procedures to Increase Throughput
    • Market Trends Toward Multiplex ELISA for Simultaneous Detection of Multiple Targets
    • Rising Importance of Food Safety Testing Fueling ELISA Adoption
    • Advancements in Biomarker Discovery Driving ELISA Usage in Clinical Trials
    • Consumer Demand for Rapid Diagnostic Tests Influencing ELISA Kit Developments
    • Expansion of Point-of-Care Testing Incorporating ELISA Technologies
    • Future Directions: Integration of AI for Enhanced Data Analysis in ELISA Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sandwich ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sandwich ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sandwich ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Indirect ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Indirect ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Indirect ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Multiple & Portable ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Multiple & Portable ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Multiple & Portable ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION